Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
- PMID: 31684985
- PMCID: PMC6827249
- DOI: 10.1186/s13046-019-1412-8
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
Abstract
Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approximately 3 months in patients with advanced HCC compared with placebo. Molecular targeted agents were developed during the 10-year period from 2007 to 2016, but every test of these agents from phase II or phase III clinical trial failed due to a low response rate and high toxicity. In the 2 years after, 2017 through 2018, four successful novel drugs emerged from clinical trials for clinical use. As recommended by updated Barcelona Clinical Liver cancer (BCLC) treatment algorithms, lenvatinib is now feasible as an alternative to sorafenib as a first-line treatment for advanced HCC. Regorafenib, cabozantinib, and ramucirumab are appropriate supplements for sorafenib as second-line treatment for patients with advanced HCC who are resistant, show progression or do not tolerate sorafenib. In addition, with promising outcomes in phase II trials, immune PD-1/PD-L1 checkpoint inhibitors nivolumab and pembrolizumab have been applied for HCC treatment. Despite phase III trials for nivolumab and pembrolizumab, the primary endpoints of improved OS were not statistically significant, immune PD-1/PD-L1 checkpoint therapy remains to be further investigated. This review summarizes the development and progression of molecular targeted and immune-based checkpoint therapies in HCC.
Keywords: Hepatocellular carcinoma; Immunotherapy; Molecular targeted therapy.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6827249/bin/13046_2019_1412_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6827249/bin/13046_2019_1412_Fig2_HTML.gif)
Similar articles
-
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.J Natl Cancer Inst. 2021 Feb 1;113(2):123-136. doi: 10.1093/jnci/djaa119. J Natl Cancer Inst. 2021. PMID: 32898239 Free PMC article.
-
Molecular therapies for HCC: Looking outside the box.J Hepatol. 2020 Feb;72(2):342-352. doi: 10.1016/j.jhep.2019.09.010. J Hepatol. 2020. PMID: 31954496 Review.
-
Review article: new therapeutic interventions for advanced hepatocellular carcinoma.Aliment Pharmacol Ther. 2020 Jan;51(1):78-89. doi: 10.1111/apt.15573. Epub 2019 Nov 20. Aliment Pharmacol Ther. 2020. PMID: 31747082 Review.
-
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.Semin Liver Dis. 2018 Nov;38(4):379-388. doi: 10.1055/s-0038-1673621. Epub 2018 Oct 24. Semin Liver Dis. 2018. PMID: 30357775
-
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.Oncology. 2017;92 Suppl 1:50-62. doi: 10.1159/000451016. Epub 2017 Feb 2. Oncology. 2017. PMID: 28147363 Review.
Cited by
-
Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth.PLoS One. 2024 May 2;19(5):e0299522. doi: 10.1371/journal.pone.0299522. eCollection 2024. PLoS One. 2024. PMID: 38696452 Free PMC article.
-
Developing risk models and subtypes of autophagy-associated LncRNAs for enhanced prognostic prediction and precision in therapeutic approaches for liver cancer patients.Oncol Res. 2024 Mar 20;32(4):703-716. doi: 10.32604/or.2023.030988. eCollection 2024. Oncol Res. 2024. PMID: 38560571 Free PMC article.
-
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.World J Gastroenterol. 2024 Feb 28;30(8):843-854. doi: 10.3748/wjg.v30.i8.843. World J Gastroenterol. 2024. PMID: 38516240 Free PMC article.
-
Pyrimethamine upregulates BNIP3 to interfere SNARE-mediated autophagosome-lysosomal fusion in hepatocellular carcinoma.J Pharm Anal. 2024 Feb;14(2):211-224. doi: 10.1016/j.jpha.2023.05.014. Epub 2023 Jun 1. J Pharm Anal. 2024. PMID: 38464783 Free PMC article.
-
Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.World J Clin Cases. 2024 Jan 16;12(2):285-292. doi: 10.12998/wjcc.v12.i2.285. World J Clin Cases. 2024. PMID: 38313649 Free PMC article.
References
-
- Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7. - DOI - PubMed
-
- Elkhoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Rd WT. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492. doi: 10.1016/S0140-6736(17)31046-2. - DOI - PMC - PubMed
-
- Finn R, Chan SL, Zhu AX, Knox J, Cheng A, Siegel A, Bautista O, Watson PA, Kudo M. Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study. J Clin Oncol. 2016;35(4_suppl):TPS503–503TPS503. doi: 10.1200/JCO.2017.35.4_suppl.TPS503. - DOI
Publication types
MeSH terms
Substances
Grants and funding
- NO.81660498/Regional science fund project of China natural science foundation
- NO. 81803007/Youth talent fund project of China natural science foundation
- NO. 2016GXNSFBA380090/Youth talent fund project of GuangXi natural science foundation
- NO.2018GXNSFBA281030/Youth talent fund project of GuangXi natural science foundation
- NO.2018GXNSFBA281091/Youth talent fund project of GuangXi natural science foundation
LinkOut - more resources
Full Text Sources
Medical
Research Materials